Integra LifeSciences (IART) Tops Q2 EPS by 2c; Offers FY22 Guidance

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.82, $0.02 better than the analyst estimate of $0.80. Revenue for the quarter came in at $398 million versus the consensus estimate of $395.65 million.

GUIDANCE:

Integra LifeSciences sees FY2022 EPS of $3.21-$3.29, versus the consensus of $3.31. Integra LifeSciences sees FY2022 revenue of $1.56-1.58 billion, versus the consensus of $1.59 billion.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

You May Also Be Interested In

• Integra LifeSciences Announces Key Executive Appointments
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Bernstein SocGen Group Reiterates Outperform Rating on Hermes International (RMS:FP) (HESAY) after cautious commentary